L1CAM and prostate carcinoma: This study has, for the first time, shown that patients who develop skeletal metastasis from prostate cancer tend to have the highest levels of the L1CAM, a finding potentially useful for clinical practice in the early diagnosis of prostate cancer bone metastasis.